Inovio Pharmaceuticals Inc. $(INO)$ will participate in several upcoming scientific and investor conferences. On February 18, the company will present a poster session at the American Association for Cancer Research Immuno-Oncology Conference in Los Angeles, focusing on the treatment of RRP with DNA immunotherapy INO-3107. On February 25, Inovio will join a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which can be accessed via webcast at https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/degYsHNqjq4UMJYMr4minN. The company will also deliver a presentation at the Festival of Biologics in San Diego on March 4, discussing the safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in a Phase 1 trial. Additionally, Inovio will participate in a fireside chat at the Citizens Life Sciences Conference in Miami Beach on March 10, with a webcast available at https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/j7XuLLN6VFvrBMcQmqB55w. Replay of the investor events will be available for 90 days at the provided links and on the INOVIO events page. Abstracts will be shared on INOVIO’s website following the presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH86033) on February 12, 2026, and is solely responsible for the information contained therein.